Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059253 | 0.87 | CES2 (0.44) | SMN1; SMN2MEN1KMT2AKDM4CGAA | |
| SCHEMBL3064785 | 0.87 | RAB9A (0.49) | SMN1; SMN2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL13138821 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AKDM4CGAA | |
| SCHEMBL3068022 | 0.84 | VNN1 (0.48) | SMN1; SMN2 | |
| SCHEMBL3054472 | 0.83 | MEN1 (0.49) | MEN1KMT2AKDM4CGAAKDM4D | |
| SCHEMBL27543079 | 0.80 | AKR1C3 (0.52) | SMN1; SMN2MEN1KMT2AGAAAKR1C3 | |
| SCHEMBL1070529 | 0.79 | HTT (0.50) | SMN1; SMN2MEN1KMT2AKDM4CCYP2C9 | |
| SCHEMBL3059687 | 0.79 | CYP11B1 (0.48) | SMN1; SMN2MEN1KMT2ACYP2C19LMNA | |
| SCHEMBL3059130 | 0.75 | HTT (0.47) | SMN1; SMN2KMT2AKDM4CGAACYP2C19 | |
| SCHEMBL7850570 | 0.74 | AKR1C3 (0.62) | MEN1KMT2AKDM4CGAAKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128431-B | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV | 2011-05-25 | — | — | CN | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| CN-101128428-A | Pyridine derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| CN-101128431-A | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1858853-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1853564-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | Janssen Pharmaceutica N.V. (BE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| WO-2006091769-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091800-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | KCNQ1, KCNQ2, KCNJ2 | SMN1; SMN2 1987/4885MEN1 2941/4885KMT2A 661/4885 |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | KCNJ2, KCNQ2, KCNQ1 | SMN1; SMN2 963/4885MEN1 3681/4885KMT2A 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.